Mode
Text Size
Log in / Sign up
Phase 3 N=121 Randomized Single-blind Diagnostic

Comparison of Two Needle Aspiration Techniques for Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) in Solid Pancreatic Lesions

Pancreatic Solid Lesions · Pancreatic Mass

Enrolled (actual)
121
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcome: Primary: Diagnostic Yield of Capillary Technique — 75.4 percentage of specimen

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Standard technique EUS-FNA (Device); Capillary suction technique for EUS FNA (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Johns Hopkins University
Primary completion
Jan 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Diagnostic Yield of Capillary Technique
75.4
PRIMARY
Diagnostic Yield of Standard Technique
65
PRIMARY
Sensitivity of EUS-FNA With Capillary Technique
45; 0; 3; 4
PRIMARY
Sensitivity of EUS-FNA With StandardTechnique
39; 5
PRIMARY
Sensitivity of EUS-FNA
88.6; 93.7 0.47
SECONDARY
First Pass Diagnostic Rate
23; 26 0.71
SECONDARY
Acquisition of Core Tissue
28; 37 0.15
SECONDARY
Diagnostic Accuracy of EUS-FNA
88; 93.8 0.46

Summary

The aim of this study is to compare Endoscopic Ultrasound and Fine Needle Aspirate with a standard 22-gauge needle using either "standard-suction" or "capillary suction" methods for solid pancreatic lesions. Investigators hope to discover the best technique for obtaining diagnostic material when patients with a pancreatic mass undergo endoscopic ultrasound and fine needle aspirate procedure. There are currently several techniques for obtaining tissue during endoscopic ultrasound and fine needle aspirate. The procedure will be performed by either the capillary suction technique or no suction technique.

Eligibility Criteria

Inclusion Criteria

  • In-patients and out-patients between the age of 18years and 90 years with pancreatic masses presenting for EUS-FNA

Exclusion Criteria

  • Uncorrectable coagulopathy (INR > 1.5)
  • Uncorrectable thrombocytopenia (platelet < 50,000)
  • Uncooperative patients
  • Pregnant women (women of childbearing age will undergo urine pregnancy testing, which is routine for all endoscopic procedures)
  • Refusal to consent form
  • Cystic lesions
  • Inaccessible lesions to EUS
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01936467). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search